Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS4131 in Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
NCT07903636Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of QLS4131 in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
QLS4131
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07903636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07903636.